EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Nvidia Develops New Location-Verification Technology for AI Chips 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Boryung Pharmaceutical has added Eli Lily's Gemzar among the anti-cancer drugs that it has rights to distribute in South Korea.
Boryung also has distribution rights to such anti-cancer drugs as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
Boryung CEO Ahn Jae-hyun promised to continue growing its anti-cancer portfolio as the company's focal point.
Gemzar (gemcitabine), a nucleoside metabolic inhibitor, is mainly a pancreatic cancer treatment drug.
Combined with other drugs, Gemzar is used for the treatment of metastatic breast cancer, advanced ovarian cancer, and non-small cell lung cancer.
Gemzar posted 14.2 billion won in revenue in South Korea last year.
